Novartis says Cosentyx could be used as an early intervention in psoriasis after new data suggests it is the first drug of its kind to modify the course of the disease. The Swiss big pharma ...

It’s two years since Novartis got its Cosentyx IL-17 drug approved for the spinal disease ankylosing spondylitis, and the Swiss pharma company has new data that it hopes will allow it to compete ...

This is a MedPage Today story. In late September, Hurricane Helene damaged a major supplier of intravenous (IV) fluids. In this report, we follow up on what has happened since. Hurricane Helene ...

Negative pressure wound therapy and antibacterial IV site management products were ... Strong demand for important goods, such as Entresto and Cosentyx, which witnessed increases in sales of ...